From PsychonautWiki
Jump to navigation Jump to search
Summary sheet: 2C-T-2
Chemical Nomenclature
Common names 2C-T-2, Rosy
Substitutive name 4-Ethylthio-2,5-dimethoxyphenethylamine
Systematic name 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine
Class Membership
Psychoactive class Psychedelic
Chemical class Phenethylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 3 mg
Light 5 - 10 mg
Common 10 - 20 mg
Strong 20 - 30 mg
Heavy 25 - 30 mg +
Total 6 - 10 hours
Onset 30 - 60 minutes
Peak 2.5 - 5 hours
Offset 2 - 4 hours
After effects 2 - 6 hours

Threshold 1 mg
Light 5 - 10 mg
Common 10 - 20 mg
Strong 20 - 25 mg
Heavy 25+ mg
Total 3 - 7 hours
Onset 5 - 15 minutes
Peak 2 - 4 hours
Offset 1 - 2 hours
After effects 2 - 4 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


2,5-Dimethoxy-4-ethylthiophenethylamine (also known as 2C-T-2, and Rosy) is a psychedelic substance of the phenethylamine chemical class that produces psychedelic effects when administered. It is a member of the 2C-x family of psychedelic phenethylamines, all of which were derived from the systematic modification of the mescaline molecule.

2C-T-2 was first synthesized and tested for activity in humans by Alexander Shulgin in 1981[1] and described in his 1991 book PiHKAL ("Phenethylamines I Have Known and Loved").[2] It is a member of the so-called "magical half-dozen" which refers to Shulgin's self-rated most important phenethylamine-derived compounds, all of which except mescaline he developed and synthesized himself. They are found within the first book of PiHKAL, and are as follows: mescaline, DOM, 2C-B, 2C-E, 2C-T-2 and 2C-T-7.[3]

Anecdotal reports generally characterize 2C-T-2 as a highly dose sensitive psychedelic known for its open headspace and unpredictable body load.

Very little data exists about the pharmacological properties, metabolism, and toxicity of 2C-T-2, and it has a relatively short history of human usage. Many reports also indicate that its physical effects may be too severe for those who are not already experienced with psychedelics or suffer from pre-existing physical conditions. It is highly advised to approach this hallucinogenic substance with the proper amount of precaution and harm reduction practices if using it.

History and culture

History icon.svg

This History and culture section is a stub.

As a result, it may contain incomplete or wrong information. You can help by expanding it.

Following the initial positive results found by Shulgin's research group, a more formal study was carried out by psychedelic psychotherapy pioneer Myron J. Stolaroff who was interested in evaluating the potential use of 2C-T-2 in psychotherapy.[4] Based on the experiences of forty participants in the study who took 2C-T-2, Stolaroff compared the effects favorably to MDMA, describing it as more emotionally opening and permitting a wider exploration of feelings and thoughts.


Generic structure of a phenethylamine molecule

2C-T-2, or 2,5-dimethoxy-4-ethylthiophenethylamine, is a substituted phenethylamine featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain. 2C-T-2 belongs to the 2C family of phenethylamines which contain methoxy functional groups CH3O- attached to carbons R2 and R5 of the benzene ring. 2C-T-2 is also substituted at R4 with an ethyl thioether group.

2C-T-2 is a close structural analogue of 2C-T-7; the two differ by the length of the alkane chain in their thioether functional group.[2]


Further information: Serotonergic psychedelic

The mechanism of action that produces 2C-T-2’s hallucinogenic and entheogenic effects has not been established in scientific literature; however, its primary psychedelic effects are more than likely a result of its efficacy at the 5-HT2A receptor as a partial agonist. This mechanism of action is shared by many other psychedelic phenethylamines and tryptamines.

Athough no established scientific experiments have been performed to establish MAO-A inhibition of 2C-T-2, phenethylamine derivatives substituted with an alkylthio group at the 4 position (4-MTA, and the 2,5-desmethoxy derivative of 2C-T-7) are known to act as selective monoamine oxidase A inhibitors.[citation needed] Furthermore, many compounds of the amphetamine-analogs of the 2C-T-x have been found to have highly selective MAO-A inhibition[5]. Therefore, this substance may likewise have MAOI effects.[6]

However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Cognitive effects

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential


This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

The toxicity and long-term health effects of recreational 2C-T-2 use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown.

Anecdotal reports suggest that there are no negative health effects attributed to trying this drug, but nothing can be completely guaranteed.

It is strongly recommended that one use harm reduction practices when using this substance.

Dependence and abuse potential

2C-T-2 is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 2C-T-2 is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 2C-T-2 presents cross-tolerance with all psychedelics, meaning that after the consumption of 2C-T-2 all psychedelics will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

If 2C-T-2 does have MAOI effects as has been speculated,[citation needed] this could indicate that 2C-T-2 is more likely to induce serotonin syndrome or general neurotransmitter overload (especially at high dosages) than other serotonergic psychedelics.[5] This may make it dangerous to combine it with other MAOIs, stimulants and certain substances which promotes the release of neurotransmitters such as serotonin or dopamine. These substances include but are not limited to:

Legal status

In November 2003, the European Council decided that 2C-T-2 shall be subjected by the Member States to control measures and criminal penalties within three months.[7]

  • Australia: 2C-T-2 is illegal in Australia as of 2005.[citation needed]
  • Austria: 2C-T-2 is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).[citation needed]
  • Belgium: 2C-T-2 was added to the list of illegal psychotropic substances on Nov 8, 2004.[citation needed]
  • Brazil: 2C-T-2 is illegal to possess, produce and sell as it is listed on Portaria SVS/MS nº 344.[8]
  • Canada: 2C-T-2 would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.[9]
  • China: As of October 2015, 2C-T-2 is a controlled substance in China.[10]
  • Denmark: 2C-T-2 was added to category B of the controlled substances list on August 23, 2003.[11][verification needed]
  • Germany: 2C-T-2 is controlled under Anlage I BtMG (Narcotics Act, Schedule I)[12] as of October 10, 1998.[13] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[14]
  • Italy: 2C-T-2 was added to the "Tabella 1" in a Jan 11, 2005 Ministry of Health statement.[citation needed]
  • Japan: 2C-T-2 is controlled as a "Designated Substance" (Shitei-Yakubutsu) by the Pharmaceutical Affairs Law, making it illegal to possess or sell.[citation needed]
  • Latvia: 2C-T-2 is a Schedule I controlled substance.[15]
  • The Netherlands: 2C-T-2 was classified as an unregistered pharmaceutical as of April 12, 1999. Unlicensed manufacture, sale, import, trade and possession of this substance can be prosecuted.[citation needed]
  • Switzerland: 2C-T-2 is a controlled substance specifically named under Verzeichnis D.[16]
  • United Kingdom: 2C-T-2 is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.[17]
  • United States: 2C-T-2 is a Schedule 1 drug in the U.S., making it illegal to possess, manufacture, or import.[citation needed]

See also

External links



  1. Alexander Shulgin (1982). Pharmacology Notes IV (The Shulgin Lab Books) (PDF). Lafayette, CA, USA: Erowid. p. 474. 
  2. 2.0 2.1 Alexander Shulgin; Ann Shulgin (1991). "#40. 2C-T-2". PiHKAL: A Chemical Love Story. United States: Transform Press. ISBN 0963009605. OCLC 1166889264. 
  3. Alexander Shulgin; Ann Shulgin (1991). PiHKAL: A Chemical Love Story. United States: Transform Press. ISBN 0963009605. OCLC 1166889264. 
  4. Stolaroff, M. J.; Wells, C. (1993). "Preliminary results with new psychoactive agents 2C-T-2 and 2C-T-7" (PDF). In Rätsch, C.; Baker, J. Jahrbuch für Ethnomedizin und Bewußtseinsforschung [Yearbook of Ethnomedicine and the Study of Consciousness]. 2. Multidisciplinary Association for Psychedelic Studies (MAPS). pp. 99–117. 
  5. 5.0 5.1 Gallardo-Godoy, A.; Fierro, A.; McLean, T. H.; Castillo, M.; Cassels, B. K.; Reyes-Parada, M.; Nichols, D. E. (2005). "Sulfur-Substituted α-Alkyl Phenethylamines as Selective and Reversible MAO-A Inhibitors:  Biological Activities, CoMFA Analysis, and Active Site Modeling". Journal of Medicinal Chemistry. 48 (7): 2407–2419. doi:10.1021/jm0493109. eISSN 1520-4804. ISSN 0022-2623. OCLC 39480771. PMID 15801832. 
  6. Theobald, D. S.; Maurer, H. H. (2007). "Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series)". Biochemical Pharmacology. 73 (2): 287–297. doi:10.1016/j.bcp.2006.09.022. eISSN 1873-2968. ISSN 0006-2952. OCLC 01536391. PMID 17067556. 
  7. "COUNCIL DECISION 2003/847/JHA". Official Journal of the European Union. Office for Official Publications of the European Communites (published December 6, 2003). November 27, 2003. pp. 64–65. OCLC 52224955. L 321. 
  8. "RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016" (in Portuguese). Agência Nacional de Vigilância Sanitária (ANVISA) [Brazilian Health Regulatory Agency (ANVISA)]. December 5, 2016. 
  9. "Schedule III". Controlled Drugs and Substances Act (CDSA). Isomer Design. Retrieved October 10, 2020. 
  10. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). 国家食品药品监督管理总局 [China Food and Drug Administration (CFDA)]. September 27, 2015. Archived from the original on September 6, 2017. 
  11. "I Nimekiri" (PDF) (in Estonian). p. 1. 
  12. "Gesetz über den Verkehr mit Betäubungsmitteln: Anlage I" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  13. "Zwölfte Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (PDF). Bundesgesetzblatt Jahrgang 1998 Teil I Nr. 68 (in German). Bundesanzeiger Verlag (published October 9, 1998). October 7, 1998. p. 3126. ISSN 0341-1095. OCLC 231871244. 
  14. "Gesetz über den Verkehr mit Betäubungsmitteln: § 29" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  15. "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020. 
  16. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  17. "Schedule 2: Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved August 20, 2020.